AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11527684 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy (etoposide, ifosfamide, doxorubicin)
Number of subjects: 59
Study 11527684 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy
Number of subjects: 59
Study 9249621 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy patients
Number of subjects: 39
Study 8495829 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal variceal ligation
Number of subjects: 23
Study 8495829 — intervention group
Group type: COMPARATOR
Intervention: Esophageal variceal sclerotherapy
Number of subjects: 23
Study 8495829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 2892257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg nocte
Number of subjects: 777
Study 2892257 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 777
Study 28501869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) progesterone 50 mg in oil, single daily injection
Number of subjects: 34
Study 28501869 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone 200 mg micronized, 3 times daily
Number of subjects: 34
Study 28501869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) progesterone
Number of subjects: 34
Study 28501869 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone
Number of subjects: 34
Study 28501869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IM and vaginal progesterone
Number of subjects: 34
Study 27464544 — intervention group
Group type: EXPERIMENTAL
Intervention: Once Vex(GM-CSF) and adriamycin
Number of subjects: 102
Study 27464544 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 102
Study 25002196 — intervention group
Group type: EXPERIMENTAL
Intervention: Shun-Qi-Tong-Xie Granule (SQTX Granule)
Number of subjects: 0
Study 25002196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22436955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 1000
Study 22436955 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 1000
Study 22436955 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 1000
Study 20393026 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) with 4 weeks' PSK administration
Number of subjects: 30
Study 20393026 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemoradiotherapy (CRT)
Number of subjects: 30
Study 18468761 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal mucoadhesive tablet containing herbal formulation
Number of subjects: 56
Study 18468761 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formulation ingredients (sage, Echinacea, Lavender, Mastic gum)
Number of subjects: 56
Study 15991060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine anal block (1 percent lidocaine)
Number of subjects: 26
Study 15991060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 26
Study 12917867 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based therapy (n=34)
Number of subjects: 66
Study 12917867 — intervention group
Group type: COMPARATOR
Intervention: Hospital rehabilitation (n=32)
Number of subjects: 66
Study 10343785 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (0.038 mg kg‐1)
Number of subjects: 16
Study 10343785 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 8865515 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 8865515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1746465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (0.5 mg)
Number of subjects: 20
Study 1746465 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary diltiazem (0.5 mg) with placebo pretreatment
Number of subjects: 20
Study 1746465 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary diltiazem (0.5 mg) with isosorbide dinitrate pretreatment
Number of subjects: 20
Study 7102536 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10, 20, and 40 mg four times a day)
Number of subjects: 52
Study 7102536 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (2.5, 5, and 10 mg four times a day)
Number of subjects: 52
Study 31595861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion program (8-week group-based adaptation)
Number of subjects: 27
Study 30143387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride nasal gel at 6.0mg/g
Number of subjects: 60
Study 30143387 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride nasal gel at 4.5mg/g
Number of subjects: 60
Study 30143387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both concentrations (6.0mg/g and 4.5mg/g)
Number of subjects: 60
Study 29016583 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal pre-peritoneal repair
Number of subjects: 102
Study 29016583 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein's hernioplasty
Number of subjects: 102
Study 25835116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 70
Study 25835116 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (Control)
Number of subjects: 70
Study 25022116 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (warming needling manipulation at key acupoints Hegu (LI 4) and Taichong (LR 3), once a day for 10 treatments, 2 sessions total)
Number of subjects: 60
Study 25022116 — intervention group
Group type: COMPARATOR
Intervention: Medication (2.5 mg diazepam tablets, three times a day for 23 days)
Number of subjects: 60
Study 22964862 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief training program for providers
Number of subjects: 0
Study 22964862 — intervention group
Group type: EXPERIMENTAL
Intervention: More complete training
Number of subjects: 0
Study 22964862 — intervention group
Group type: COMPARATOR
Intervention: Less training
Number of subjects: 0
Study 20026538 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients diagnosed with mediastinitis or endocarditis during follow-up
Number of subjects: 838
Study 20026538 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative variables
Number of subjects: 838
Study 20026538 — intervention group
Group type: COMPARATOR
Intervention: Type of antibiotic prophylaxis
Number of subjects: 838
Study 18089867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQOL scores (EORTC QLQ-C30 and EORTC Brain Cancer Module)
Number of subjects: 247
Study 18089867 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical analysis
Number of subjects: 247
Study 18089867 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined analyses
Number of subjects: 247
Study 18089867 — intervention group
Group type: EXPERIMENTAL
Intervention: C indexes and R2 coefficients
Number of subjects: 247
Study 14707430 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based emulsion (0.16 g/kg/h for 3 hours)
Number of subjects: 13
Study 14707430 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil + medium chain fatty acid (MCT) emulsion (0.16 g/kg/h for 3 hours)
Number of subjects: 13
Study 14707430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data on day 1
Number of subjects: 13
Study 14707430 — intervention group
Group type: COMPARATOR
Intervention: Both lipid emulsions
Number of subjects: 13
Study 11367869 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (intramuscular methotrexate 12.5 mg/week, oral sulphasalazine 0.5 g b.i.d., indometacin 100 mg suppository at bed-time)
Number of subjects: 30
Study 11367869 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus antioxidant combination
Number of subjects: 30
Study 11367869 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of vitamin E (400 mg t.i.d.) plus standard treatment
Number of subjects: 30
Study 9226553 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary gas chromatography with nitrogen-phosphorus selective detection (NPD)
Number of subjects: 0
Study 8428267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine wound infiltration
Number of subjects: 60
Study 8428267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3676625 — intervention group
Group type: COMPARATOR
Intervention: Out-patient care
Number of subjects: 106
Study 3676625 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment (psychotherapy)
Number of subjects: 106
Study 3676625 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment (all forms of day care)
Number of subjects: 106
Study 31608503 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD) alone (Group A)
Number of subjects: 71
Study 31608503 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session ERCP combined with EUS-guided gallbladder drainage (Group B)
Number of subjects: 71
Study 28710229 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of antibiotic therapy
Number of subjects: 500
Study 28710229 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy
Number of subjects: 500
Study 28710229 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised duration determined by clinical response and 75% reduction in peak C reactive protein (CRP) values
Number of subjects: 500
Study 26338453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training + healthy diet (RT-HD)
Number of subjects: 0
Study 26338453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 0
Study 26338453 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 23257314 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mg po mibampator
Number of subjects: 132
Study 23257314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 22001199 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg glucosamine sulfate
Number of subjects: 59
Study 22001199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19723701 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus ICD (1089 patients)
Number of subjects: 1820
Study 19723701 — intervention group
Group type: COMPARATOR
Intervention: ICD alone (731 patients)
Number of subjects: 1820
Study 19723701 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus ICD
Number of subjects: 1820
Study 19723701 — intervention group
Group type: COMPARATOR
Intervention: CRT plus ICD and ICD alone
Number of subjects: 1820
Study 17846273 — intervention group
Group type: EXPERIMENTAL
Intervention: AN1792(QS‐21) (synthetic beta‐amyloid plus an adjuvant)
Number of subjects: 372
Study 17846273 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (placebo)
Number of subjects: 372
Study 15851238 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Number of subjects: 1153
Study 15851238 — intervention group
Group type: COMPARATOR
Intervention: No angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Number of subjects: 1153
Study 15851238 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI) in patients with congestive heart failure or impaired left ventricular function
Number of subjects: 1153
Study 11437040 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP needle
Number of subjects: 30
Study 11437040 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson-Cook needle
Number of subjects: 30
Study 10178333 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based smoking control intervention (4 years, 1989-1992)
Number of subjects: 9875
Study 7526007 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of American Urological Association symptom score
Number of subjects: 0
Study 7526007 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of peak urine flow rate
Number of subjects: 0
Study 7526007 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of prostate specific antigen (PSA)
Number of subjects: 0
Study 2752739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanolin allergens
Number of subjects: 33
Study 2752739 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified anhydrous lanolin
Number of subjects: 33
Study 2752739 — intervention group
Group type: COMPARATOR
Intervention: Commercial cream containing 6% purified lanolin
Number of subjects: 33
Study 1157005 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) (75 mg/m2/day)
Number of subjects: 313
Study 1157005 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX) (25 mg/m2/twice weekly)
Number of subjects: 313
Study 1157005 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide (CYC) (100 mg/m2/day)
Number of subjects: 313
Study 29800338 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT-PM
Number of subjects: 101
Study 29800338 — intervention group
Group type: COMPARATOR
Intervention: Pain Module counseling only
Number of subjects: 101
Study 29800338 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 101
Study 27208039 — intervention group
Group type: EXPERIMENTAL
Intervention: EN+PN
Number of subjects: 80
Study 27208039 — intervention group
Group type: COMPARATOR
Intervention: EN
Number of subjects: 80
Study 25312400 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (PA)
Number of subjects: 384
Study 25312400 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited screen time (ST)
Number of subjects: 384
Study 25312400 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate fruits and vegetables consumption (FV)
Number of subjects: 384
Study 25312400 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (PA)
Number of subjects: 384
Study 25312400 — intervention group
Group type: COMPARATOR
Intervention: Weight status (normal weight and overweight/obese)
Number of subjects: 384
Study 23953528 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 60
Study 23953528 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Number of subjects: 60
Study 23953528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NS and Plasmalyte
Number of subjects: 60
Study 21741088 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab with immunomodulator
Number of subjects: 692
Study 21741088 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab in adults
Number of subjects: 692
Study 21741088 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent immunomodulator use (purine antimetabolites or methotrexate)
Number of subjects: 692
Study 21741088 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of antibodies to infliximab (ATIs)
Number of subjects: 692
Study 19536422 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Number of subjects: 424
Study 19536422 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 424
Study 17645255 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation of points plus Wenlafaxin
Number of subjects: 70
Study 17645255 — intervention group
Group type: COMPARATOR
Intervention: Simple oral administration of Wenlafaxin
Number of subjects: 70
Study 15476688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 8
Study 15476688 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 8
Study 11355435 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment using local points ST‐6, ST‐7, SI‐18, GV‐20, GB‐20, BL‐10 and distant point LI‐4, with needles manipulated to achieve De‐qui sensation and left in situ for 30 min, administered weekly for a total of six treatments.
Number of subjects: 6
Study 9663368 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg-felodipine ER 2.5 mg once daily, titrated to a maximum of enalapril 10 mg-felodipine ER 10 mg if SiDBP not controlled after 4 weeks; Hydrochlorothiazide (HCTZ) 12.5 mg added if hypertension not controlled at maximum dose.
Number of subjects: 502
Study 9663368 — intervention group
Group type: COMPARATOR
Intervention: Enalapril-felodipine ER combination with HCTZ 12.5 mg
Number of subjects: 502
Study 8113301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage from OA knees
Number of subjects: 15
Study 8113301 — intervention group
Group type: COMPARATOR
Intervention: Control cartilage from cadaver knees
Number of subjects: 15
Study 2571216 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 17582 B (50 mg orally)
Number of subjects: 14
Study 2571216 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (10 mg orally)
Number of subjects: 14
Study 969072 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted pyeloplasty
Number of subjects: 129
Study 969072 — intervention group
Group type: COMPARATOR
Intervention: Unsplinted pyeloplasty
Number of subjects: 129
Study 30165494 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA‐mandated addiction warning
Number of subjects: 672
Study 30165494 — intervention group
Group type: COMPARATOR
Intervention: Reduced‐risk warnings
Number of subjects: 672
Study 28644774 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with chemotherapy (two doses of GO during induction and intensification)
Number of subjects: 816
Study 28644774 — intervention group
Group type: COMPARATOR
Intervention: Standard five-course chemotherapy alone (No-GO arm)
Number of subjects: 816
Study 28644774 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with chemotherapy
Number of subjects: 816
Study 26196193 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO ± smoke inhalation acute lung injury (SALI)
Number of subjects: 43
Study 26196193 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventilation only ± SALI)
Number of subjects: 43
Study 26196193 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO groups
Number of subjects: 43
Study 23657796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecosystem-based intervention
Number of subjects: 0
Study 23657796 — intervention group
Group type: COMPARATOR
Intervention: Individually focused intervention
Number of subjects: 0
Study 17063425 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic bevacizumab (5 mg/kg), administered three times at 2-week intervals.
Number of subjects: 25
Study 17063425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1 mg), administered up to three times at 4-week intervals.
Number of subjects: 25
Study 14560207 — intervention group
Group type: EXPERIMENTAL
Intervention: Color flow duplex ultrasound scanning (CDU)
Number of subjects: 281
Study 14560207 — intervention group
Group type: COMPARATOR
Intervention: Computed tomographic scan (CT)
Number of subjects: 281
Study 14560207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CDU and CT
Number of subjects: 281
Study 10320603 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA) with background infusion (BI) at 15 microg x kg(‐1) x h(‐1) and bolus doses of 15 microg x kg(‐1) with a lock‐out interval of 10 min
Number of subjects: 47
Study 10320603 — intervention group
Group type: COMPARATOR
Intervention: Continuous Infusion (CI) at 20 to 40 microg x kg(‐1) x h(‐1)
Number of subjects: 47
Study 8938091 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced antenatal visit schedule (7 visits for nulliparous women, 6 visits for multiparous women)
Number of subjects: 1882
Study 8938091 — intervention group
Group type: COMPARATOR
Intervention: Traditional antenatal visit schedule (13 visits)
Number of subjects: 1882
Study 1725912 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 2
Study 6412795 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (200 mg) plus Placebo
Number of subjects: 30
Study 6412795 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg) plus Chlorthalidone (25 mg)
Number of subjects: 30
Study 31808594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.4 mg/kg, orally, once 2 hours before infection
Number of subjects: 12
Study 31808594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30153737 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive smoking treatment including individual counseling, free pharmacotherapy (dual nicotine replacement therapy or varenicline), and 5 weeks of contingency management.
Number of subjects: 25
Study 30153737 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control sites (no treatment during the study period).
Number of subjects: 25
Study 27895268 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education integrated into microcredit lending groups
Number of subjects: 138
Study 27895268 — intervention group
Group type: COMPARATOR
Intervention: Mixed-gender groups
Number of subjects: 138
Study 25209353 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention for cancer survivors
Number of subjects: 296
Study 25209353 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networking components of the intervention
Number of subjects: 296
Study 25209353 — intervention group
Group type: EXPERIMENTAL
Intervention: Early engagement
Number of subjects: 296
Study 23033858 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraging symbolic gesture (baby sign)
Number of subjects: 40
Study 23033858 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no gesture training)
Number of subjects: 40
Study 23033858 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture training for mothers
Number of subjects: 40
Study 21252018 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 1812
Study 21252018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1812
Study 21252018 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 1812
Study 21252018 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1812